Dr. Elena Shagisultanova, MD, PhD

Dr. Shagisultanova practices at UCHealth University of Colorado Hospital in Aurora, Colorado, part of UCHealth.

Dr. Shagisultanova's NPI, 1720365760, was assigned on November 4, 2011. Dr. Shagisultanova holds Colorado license 55547.

Dr. Shagisultanova's primary practice is UCHealth University of Colorado Hospital, at 12605 E 16th Ave, Aurora, CO 80045 in Adams County. The practice phone is (720) 848-0000.

Dr. Shagisultanova's primary practice is UCHealth University of Colorado Hospital in Aurora, Colorado, part of UCHealth. Dr. Shagisultanova is also affiliated with Thomas Jefferson University Hospital. The medical group on file is Jefferson University Physicians. Dmand AI also links Dr. Shagisultanova to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shagisultanova practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shagisultanova's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Shagisultanova's licenses on file in 3 states: Colorado, California and Pennsylvania.

CMS data shows 124 Medicare services from Dr. Shagisultanova across 2 procedure codes in 2024, all of them office visits, for 52 Medicare patients. Medicare paid $11,728 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 52 Medicare patients who saw Dr. Shagisultanova in 2024. The largest group is 65 to 74, with 19 patients. 75% of them have cancer, and 52% have high blood pressure. 35% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shagisultanova's median patient age at 55, with 97% women.

In 2024, Dr. Shagisultanova wrote 474 Medicare Part D claims for 59 patients. 75% of them were for generic drugs. CMS names the drug for 259 of them, across 12 drugs with 11 or more claims each, at $978,443 in total drug cost. In 2023, CMS named 299 claims across 14 drugs.

Dr. Shagisultanova accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shagisultanova as offering telehealth.

Dmand AI links 20 papers to Dr. Shagisultanova, published from 2014 to 2024. 2021 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Protein Kinase Inhibitors and Receptor, ErbB-2. Dr. Shagisultanova has published most often in Breast Cancer Res Treat. Dr. Shagisultanova's most frequent co-authors are Virginia F. Borges, MD, Jennifer R. Diamond, MD and Peter Kabos, MD.

Dmand AI links Dr. Shagisultanova to 5 clinical trials. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Hematologic Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Shagisultanova that name 1 trial.

CMS Open Payments shows 16 general payments to Dr. Shagisultanova from 5 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 69% of the total. Novartis Pharmaceuticals Corporation paid the most, $6,128. It also lists 13 research payments totaling $163,719 from 2022 to 2023, naming 1 clinical trial.